Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD) — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD) — Stella

Home/Sickle Cell Disease/

View on ClinicalTrials.gov

Recruiting

Back to Sickle Cell Disease trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(3 sites)

United States

The Foundation for Sickle Cell Disease, Hollywood, Florida

Southern Specialty Research, Flowood, Mississippi

Jacobi Medical Center, The Bronx, New York

Key details

Phase

Safety & dosing

Sponsor

CSL Behring

Enrollment target

~63 participants

Started

February 2026

Primary completion

June 2028

Age range

18 Years and older

Last updated February 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.